United States · Bill · S
S. 1852 (118th)
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
Introduced
7 June 2023
Last action
—
Status
Placed on Senate Legislative Calendar under General Orders. Calendar No. 201.
Sponsors
—
Subjects
Discovery layer
Source updated
27 May 2025
Summary
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 This bill reauthorizes through FY2028 the Sickle Cell Disease Treatment Demonstration Program, which supports efforts to improve treatment and prevention of sickle cell disease and complications from that disease. (Sickle cell disease is an inherited blood disorder that can lead to pain, anemia, infections, and stroke.)
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
6 official files
Reported to Senate (text)
Reported to Senate (text)
Reported to Senate · EN · 6 September 2023
Reported to Senate (PDF)
Reported to Senate · EN · 6 September 2023
Reported to Senate
summary · EN · 6 September 2023
Introduced in Senate (text)
Introduced in Senate · EN · 7 June 2023
Introduced in Senate (PDF)
Introduced in Senate · EN · 7 June 2023
Introduced in Senate
summary · EN · 7 June 2023
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/118th-congress/senate-bill/1852
- Open data entity: https://api.congress.gov/v3/bill/118/s/1852